Stock price when the opinion was issued
Shares are down because the market fears they will do a tie-up deal with Humana, but CI bowed out. This is good given Human's problems. Managers are excellent, making good deals. EPS grew 13% compounded annual growth rate from 2013-2023. Are buying back shares and pay a dividend.
(Analysts’ price target is $397.05)Sold last year, mainly because Trump administration announced seemingly negative measures toward HMO's in general and specific ones with pharmacy benefits managers. Common theme in the space is that margins are compressing. Overhang will go on for a few more quarters.
Exited, and allocated proceeds to UNH, as it's a better performer, larger scale. He also had concerns over customer concentration. Not expensive at 12x forward earnings plus 1.7% yield.